{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-035170","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2023-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.151174+00:00","generated_at":"2026-06-17T22:19:19.708273+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Praxis CCO Nicole Sweeny departs; cash runway extended to Q2 2024 via restructuring","bullets":["Nicole Sweeny, Chief Commercial Officer, to depart effective March 31, 2023; no dispute or disagreement cited.","Separation agreement provides 9 months base salary ($337,500) plus COBRA premium subsidy.","Company refocuses on ulixacaltamide end-of-Phase-2 FDA meeting, PRAX-562 and PRAX-222 readouts.","Realigned expenses and headcount expected to extend cash runway into Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-035170","json":"https://secwatch.observer/filing/0001104659-23-035170.json","markdown":"https://secwatch.observer/filing/0001104659-23-035170.md","text":"https://secwatch.observer/filing/0001104659-23-035170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000110465923035170/0001104659-23-035170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000110465923035170/tm239181d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T22:19:19.708273+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51043ed642","claim":"Nicole Sweeny departed as Chief Commercial Officer at Praxis Precision Medicines, Inc..","evidence_excerpt":"On March 17, 2023, Nicole Sweeny, Chief Commercial Officer of Praxis Precision Medicines, Inc. (the “Company”), and the Company determined that, considering the current priorities of the Company, Ms. Sweeny would depart from the Company, effective March 31, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689548/000110465923035170/0001104659-23-035170-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}